Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
17:16:30 EDT Thu 15 Oct 2026
Enter Symbol
or Name
USA
CA



Q:BLRX - BIOLINE RX LTD SPON ADR EACH REP 600 ORD SHS (P/S) - https://www.biolinerx.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
BLRX - Q0.41.80·2.500.12.05-0.025-1.228.8551122.165  2.165  1.9454.068  2.1116:10:04Oct 0815 min RT 2¢

Recent Trades - Last 10 of 112
Time ETExPriceChangeVolume
16:10:04Q2.05-0.0251
16:00:00Q2.05-0.0254
16:00:00Q2.05-0.0252
15:59:10Q2.150.07523
15:57:47Q2.05-0.025100
15:47:00Q2.03-0.045100
15:47:00Q2.03-0.04586
15:46:59Q2.01-0.06532
15:45:09Q2.00-0.07529
15:43:47Q1.97-0.10529

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2026-10-08 07:00U:BLRXNews ReleaseBioLineRx and Hemispherian Announce Two GLIX1 Presentations at the 31st Society for Neuro-Oncology (SNO) Annual Meeting & Education Day
2026-09-10 07:00U:BLRXNews ReleaseBioLineRx and Hemispherian AS to Present Encouraging GLIX1 Preclinical Efficacy Data and its Phase 1/2a Trial Design at the 21st Meeting of the European Association of Neuro-Oncology (EANO 2026)
2026-08-31 07:00U:BLRXNews ReleaseBioLineRx Reports Second Quarter 2026 Financial Results and Provides Corporate Update
2026-08-28 08:00U:BLRXNews ReleaseBioLineRx Announces $3.75 Million Registered Direct Offering and Concurrent Private Placement
2026-08-25 07:00U:BLRXNews ReleaseBioLineRx to Report Second Quarter 2026 Results on August 31, 2026
2026-07-20 07:00U:BLRXNews ReleaseBioLineRx and Hemispherian AS to Present Data Demonstrating Strong Synergy of GLIX1 with PARP Inhibitors in HR-Proficient Ovarian Cancers at ESMO 2026
2026-07-08 07:00U:BLRXNews ReleaseBioLineRx and Hemispherian Announce New Preclinical Data Demonstrating Strong Synergistic Effect between GLIX1 and PARP Inhibitor in a Patient-Derived Ovarian Cancer Xenograft Model
2026-05-27 07:00U:BLRXNews ReleaseBioLineRx Reports First Quarter 2026 Financial Results and Provides Corporate Update
2026-05-22 07:00U:BLRXNews ReleaseBioLineRx and Hemispherian AS Highlight New Data on GLIX1 at the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting
2026-05-20 07:00U:BLRXNews ReleaseBioLineRx to Report First Quarter 2026 Results on May 27, 2026
2026-05-19 07:00U:BLRXNews ReleaseBioLineRx and Hemispherian Announce New GLIX1 Data Demonstrating Potent Anti-Tumor Effect in Glioblastoma (GBM) Across Multiple In-Vivo Studies, Including a Temozolomide (TMZ)-Resistant Model with Patient-Derived Xenografts
2026-04-28 07:00U:BLRXNews ReleaseBioLineRx and Hemispherian Announce First Patient Dosed in Phase 1/2a Study of GLIX1 for the Treatment of Glioblastoma (GBM)
2026-03-26 07:00U:BLRXNews ReleaseBioLineRx Announces Initiation of Phase 1/2a Study of GLIX1 for the Treatment of Glioblastoma (GBM)
2026-03-23 07:00U:BLRXNews ReleaseBioLineRx Reports 2025 Financial Results and Provides Corporate Update
2026-03-16 07:00U:BLRXNews ReleaseBioLineRx to Report 2025 Annual Results on March 23, 2026
2025-11-24 07:00U:BLRXNews ReleaseBioLineRx Reports Third Quarter 2025 Financial Results and Provides Corporate Update
2025-11-18 07:00U:BLRXNews ReleaseBioLineRx to Report Third Quarter 2025 Results on November 24, 2025
2025-11-17 07:00U:BLRXNews ReleaseBioLineRx Announces Receipt of USPTO Notice of Allowance for Key Patent Covering GLIX1 for Treating a Broad Range of Cancer Types